Effect of Renin-Angiotensin-Aldosterone System Blockade on Long-Term Outcomes in Postacute Kidney Injury Patients With Hypertension*
- 15 September 2020
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Critical Care Medicine
- Vol. 48 (12), e1185-e1193
- https://doi.org/10.1097/ccm.0000000000004588
Abstract
Objectives: Renal replacement therapy–requiring acute kidney injury frequently occurs in ICUs, which require evidence-based medical attention. However, in the postacute kidney injury patient population, the evidence regarding effective therapies to improve patient outcomes is lacking. Therefore, we aimed to examine whether the renin-angiotensin-aldosterone system blockade is effective in improving renal outcomes in postacute kidney injury patients who experienced temporary renal replacement therapy and have hypertension. Design: A retrospective cohort study. Setting: A nationwide database in Taiwan. Patients: From January 1, 2000, to December 31, 2013, we identified 8,558 acute kidney injury patients with hypertension in the national registry database. All these patients experienced an acute kidney injury episode, which required temporary renal replacement therapy for at least once. Interventions: Users (n = 3,885) and nonusers (n = 4,673) of angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers. Measurements and Main Results: We used Cox proportional hazards regression models to analyze hazard ratios for the commencement of end-stage renal disease and all-cause mortality for angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker users (n = 3,885) and nonusers (n = 4,673). In a median follow-up of 4.3 years, 5,880 patients (68.7%) required long-term dialysis, and 4,841 patients (56.6%) died. Compared with postacute kidney injury patients who did not use angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker, angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker users are marginally less likely to progress to end-stage renal disease (adjusted hazard ratio 0.95; 95% CI 0.90–1.01; p = 0.06) and significantly less likely to suffer from all-cause mortality (adjusted hazard ratio 0.93; 95% CI 0.87–0.98; p = 0.011). Conclusions: In patients who experienced renal replacement therapy–requiring acute kidney injury and have hypertension, angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker use is associated with better survival outcomes compared with nonuser.This publication has 66 references indexed in Scilit:
- Acute kidney injury: an increasing global concernThe Lancet, 2013
- The Impact of Dialysis-Requiring Acute Kidney Injury on Long-Term Prognosis of Patients Requiring Prolonged Mechanical Ventilation: Nationwide Population-Based StudyPLOS ONE, 2012
- The severity of acute kidney injury predicts progression to chronic kidney diseaseKidney International, 2011
- Dialysis-requiring acute renal failure increases the risk of progressive chronic kidney diseaseKidney International, 2009
- Nonrecovery of Kidney Function and Death after Acute on Chronic Renal FailureClinical Journal of the American Society of Nephrology, 2009
- Acute Kidney Injury Increases Risk of ESRD among ElderlyJournal of the American Society of Nephrology, 2009
- Acute Kidney Injury, Mortality, Length of Stay, and Costs in Hospitalized PatientsJournal of the American Society of Nephrology, 2005
- Predictors of New-Onset Kidney Disease in a Community-Based PopulationJAMA, 2004
- Outcomes in patients with normal serum creatinine and with artificial renal support for acute renal failure developing after coronary artery bypass graftingThe American Journal of Cardiology, 2004
- Taiwan’s New National Health Insurance Program: Genesis And Experience So FarHealth Affairs, 2003